Relapsed/Refractory HER2+ Metastatic Breast Cancer
This article reviews the recent development of HER2-targeted therapies with central nervous system (CNS) activity that may improve survival of patients with CNS metastases and prevent development of new CNS metastases. This article also features insights from oncology experts Adam M. Brufsky, MD, PhD; V. K. Gadi, MD, PhD; Sara A. Hurvitz, MD; and Neil M. Iyengar, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Teclistamab Combo Approval is ‘Excellent’ for R/R Multiple Myeloma
2
Refining Focal Radiotherapy Practice with HIFU in Prostate Cancer
3
Subcutaneous Amivantamab is a ‘Way to Move Forward’ in EGFR+ NSCLC Care
4
ELCC 2026: Key Updates Across Non–Small Cell Lung Cancer Populations
5